Ptc Therapeutics (PTCT) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $60.99, +2.21% vs the prior close of $59.67.
- Volume 1.05M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PTCT rises 2.2% to $60.99. Closed at $60.99, +2.21% vs the prior close of $59.67. Day range $59.88–$62.31, opened at $61.08.
PTCT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — PTCT rises 2.2% to $60.99
- Closed at $60.99, +2.21% vs the prior close of $59.67. Day range $59.88–$62.31, opened at $61.08.
- Volume was 1.05M shares, 1.0x its 50-day average of 1.05M.
- Price is -9.9% vs its 50-day average ($67.72) and -14.7% vs its 200-day average ($71.49).
- 52-week range $58.80–$90.87; today's close sits at 7% of that range, 32.9% below the 52-week high.
Oct 14, 2026 — PTCT dips 0.4% to $59.67, a 52-week low, 3 down days in a row
- Closed at $59.67, -0.42% vs the prior close of $59.92. Day range $58.80–$60.69, opened at $59.30.
- Volume was 1.52M shares, 1.4x its 50-day average of 1.05M.
- Price is -12.1% vs its 50-day average ($67.89) and -16.6% vs its 200-day average ($71.57).
- 52-week range $58.80–$90.87; today's close sits at 3% of that range, 34.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — PTCT slides 4.8% to $59.92, a 52-week low
- Closed at $59.92, -4.77% vs the prior close of $62.92. Day range $59.82–$62.75, opened at $62.64.
- Volume was 1.05M shares, 1.0x its 50-day average of 1.06M.
- Price is -12.0% vs its 50-day average ($68.07) and -16.4% vs its 200-day average ($71.67).
- 52-week range $59.82–$90.87; today's close sits at 0% of that range, 34.1% below the 52-week high.
Oct 12, 2026 — PTCT dips 2.8% to $62.92
- Closed at $62.92, -2.75% vs the prior close of $64.70. Day range $62.88–$65.03, opened at $64.80.
- Volume was 745.20K shares, 0.7x its 50-day average of 1.13M.
- Price is -7.8% vs its 50-day average ($68.24) and -12.3% vs its 200-day average ($71.76).
- 52-week range $61.23–$90.87; today's close sits at 6% of that range, 30.8% below the 52-week high.
Oct 9, 2026 — PTCT jumps 3.4% to $64.70
- Closed at $64.70, +3.42% vs the prior close of $62.56. Day range $62.20–$64.73, opened at $62.52.
- Volume was 1.17M shares, 1.0x its 50-day average of 1.13M.
- Price is -5.3% vs its 50-day average ($68.34) and -9.9% vs its 200-day average ($71.84).
- 52-week range $61.23–$90.87; today's close sits at 12% of that range, 28.8% below the 52-week high.
Oct 8, 2026 — PTCT dips 1.1% to $62.56
- Closed at $62.56, -1.06% vs the prior close of $63.23. Day range $61.65–$62.86, opened at $62.66.
- Volume was 1.23M shares, 1.1x its 50-day average of 1.13M.
- Price is -8.7% vs its 50-day average ($68.56) and -13.0% vs its 200-day average ($71.91).
- 52-week range $61.23–$90.87; today's close sits at 4% of that range, 31.2% below the 52-week high.
Oct 7, 2026 — PTCT dips 0.7% to $63.23
- Closed at $63.23, -0.74% vs the prior close of $63.70. Day range $62.84–$64.04, opened at $63.19.
- Volume was 1.04M shares, 0.9x its 50-day average of 1.14M.
- Price is -8.1% vs its 50-day average ($68.79) and -12.2% vs its 200-day average ($71.99).
- 52-week range $61.23–$90.87; today's close sits at 7% of that range, 30.4% below the 52-week high.
Oct 6, 2026 — PTCT ends flat (+0.1%) to $63.70
- Closed at $63.70, +0.08% vs the prior close of $63.65. Day range $62.92–$65.27, opened at $64.53.
- Volume was 1.26M shares, 1.1x its 50-day average of 1.15M.
- Price is -7.7% vs its 50-day average ($69.04) and -11.6% vs its 200-day average ($72.04).
- 52-week range $61.23–$90.87; today's close sits at 8% of that range, 29.9% below the 52-week high.
Oct 5, 2026 — PTCT ends flat (+0.3%) to $63.65
- Closed at $63.65, +0.30% vs the prior close of $63.46. Day range $62.60–$64.47, opened at $63.42.
- Volume was 1.04M shares, 0.9x its 50-day average of 1.15M.
- Price is -8.1% vs its 50-day average ($69.28) and -11.7% vs its 200-day average ($72.10).
- 52-week range $61.23–$90.87; today's close sits at 8% of that range, 30.0% below the 52-week high.
Oct 2, 2026 — PTCT dips 1.0% to $63.46, 4 down days in a row
- Closed at $63.46, -1.04% vs the prior close of $64.13. Day range $62.80–$65.39, opened at $64.81.
- Volume was 895.60K shares, 0.8x its 50-day average of 1.15M.
- Price is -8.7% vs its 50-day average ($69.54) and -12.1% vs its 200-day average ($72.16).
- 52-week range $61.16–$90.87; today's close sits at 8% of that range, 30.2% below the 52-week high.
- That makes 4 straight losses.
PTCT latest news & SEC filings
Every SEC filing by or about PTCT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Boulding Mark Elliott converted options/RSUs into 192 shares at $39.42 (≈$7.57K) on Oct 9, 2026; now holds 105,464
- Boulding Mark Elliott sold 192 shares at $64.26 (≈$12.34K) on Oct 9, 2026; now holds 105,272
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Schmertzler Michael sold 2,447 shares at $63.38 (≈$155.09K) on Oct 7, 2026; now holds 1,294,147
- Schmertzler Michael sold 53 shares at $63.95 (≈$3.39K) on Oct 7, 2026; now holds 1,294,094
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Boulding Mark Elliott converted options/RSUs into 1,638 shares at $39.42 (≈$64.57K) on Oct 5, 2026; now holds 106,910
- Boulding Mark Elliott sold 1,638 shares at $64.03 (≈$104.88K) on Oct 5, 2026; now holds 105,272
- Boulding Mark Elliott converted options/RSUs into 435 shares at $39.42 (≈$17.15K) on Oct 6, 2026; now holds 105,707
- Boulding Mark Elliott sold 435 shares at $64.16 (≈$27.91K) on Oct 6, 2026; now holds 105,272
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 6, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Jul 30, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $360.52M (prior year $178.88M) (+101.5% vs Jun 30, 2025)
- Net income: $83.50M (prior year -$64.85M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $0.92 (prior year -$0.83) (swung to profit vs Jun 30, 2025)
Jul 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade PTCT
- Last results release: Jul 30, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 19, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Oct 29, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.81% (largest 5.5%).
- Liquidity: about 1.32M shares (≈$80.46M) trade per day on average.
- 52-week position: $60.99 vs a range of $58.80–$90.87 (7% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Michael Schmertzler sold 376 shares on Sep 17, 2026.
- Latest filings: 8-K Sep 21, 2026; 8-K Aug 28, 2026; 8-K Aug 13, 2026.
- Share count: 83.46M shares outstanding (Jul 29, 2026), +5.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PTCT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 61.08 | 62.31 | 59.88 | 60.99 | 1.05M |
| Oct 14, 2026 | 59.30 | 60.69 | 58.80 | 59.67 | 1.52M |
| Oct 13, 2026 | 62.64 | 62.75 | 59.82 | 59.92 | 1.05M |
| Oct 12, 2026 | 64.80 | 65.03 | 62.88 | 62.92 | 745.20K |
| Oct 9, 2026 | 62.52 | 64.73 | 62.20 | 64.70 | 1.17M |
| Oct 8, 2026 | 62.66 | 62.86 | 61.65 | 62.56 | 1.23M |
| Oct 7, 2026 | 63.19 | 64.04 | 62.84 | 63.23 | 1.04M |
| Oct 6, 2026 | 64.53 | 65.27 | 62.92 | 63.70 | 1.26M |
| Oct 5, 2026 | 63.42 | 64.47 | 62.60 | 63.65 | 1.04M |
| Oct 2, 2026 | 64.81 | 65.39 | 62.80 | 63.46 | 895.60K |
| Oct 1, 2026 | 64.70 | 65.57 | 63.40 | 64.13 | 1.20M |
| Sep 30, 2026 | 65.16 | 65.50 | 64.14 | 64.78 | 1.04M |
| Sep 29, 2026 | 65.51 | 65.96 | 64.26 | 64.96 | 900.40K |
| Sep 28, 2026 | 62.35 | 66.26 | 62.30 | 65.95 | 1.91M |
| Sep 25, 2026 | 62.65 | 63.44 | 61.66 | 62.67 | 1.20M |
| Sep 24, 2026 | 62.23 | 62.76 | 61.23 | 62.28 | 1.75M |
| Sep 23, 2026 | 65.80 | 66.15 | 62.24 | 62.34 | 1.10M |
| Sep 22, 2026 | 66.24 | 66.58 | 65.36 | 65.96 | 1.31M |
| Sep 21, 2026 | 65.93 | 66.21 | 64.99 | 65.26 | 1.09M |
| Sep 18, 2026 | 68.00 | 68.00 | 65.18 | 65.37 | 3.87M |
About Ptc Therapeutics
Ptc Therapeutics (PTCT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WARREN, NJ. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1070081.
PTCT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jessica Caroline Chutter | Director | Mar 26, 2026 |
| Allan Steven Jacobson | Director | Jan 6, 2026 |
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Aug 6, 2026 |
| Stephanie Okey | Director | Mar 12, 2026 |
| Emma Reeve | Director | Jan 6, 2026 |
| Michael Schmertzler | Director | Sep 18, 2026 |
| David P Southwell | Director | Jan 6, 2026 |
| Glenn Jr Md Phd Steele | Director | Jan 6, 2026 |
| Mary L. Smith | Director | Jul 13, 2026 |
| Hege Elisabeth Sollie-Zetlmayer | Director | Jul 30, 2026 |
| Alethia Young | Director | Jan 6, 2026 |
| Jerome B Zeldis | Director | Jan 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | Jul 13, 2026 |
| Mark Elliott Boulding | EXEC. VP AND CLO | Aug 19, 2026 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | Apr 6, 2026 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | Jul 16, 2026 |
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Aug 6, 2026 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | Jun 12, 2026 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | Jun 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 17, 2026 | Michael Schmertzler | Sale | 376 | $68.45 |
| Sep 17, 2026 | Michael Schmertzler | Sale | 9,624 | $67.83 |
| Sep 16, 2026 | Michael Schmertzler | Sale | 2,994 | $66.58 |
| Sep 16, 2026 | Michael Schmertzler | Sale | 7,006 | $67.35 |
| Sep 10, 2026 | Michael Schmertzler | Sale | 10,000 | $67.34 |
| Sep 9, 2026 | Michael Schmertzler | Sale | 9,428 | $67.79 |
| Sep 9, 2026 | Michael Schmertzler | Sale | 572 | $68.67 |
| Aug 27, 2026 | Michael Schmertzler | Sale | 610 | $72.22 |
| Aug 27, 2026 | Michael Schmertzler | Sale | 11,890 | $71.55 |
| Aug 26, 2026 | Michael Schmertzler | Sale | 6,874 | $72.74 |
| Aug 26, 2026 | Michael Schmertzler | Sale | 5,626 | $73.18 |
| Aug 20, 2026 | Michael Schmertzler | Sale | 691 | $72.92 |
| Aug 20, 2026 | Michael Schmertzler | Sale | 2,390 | $71.88 |
| Aug 20, 2026 | Michael Schmertzler | Sale | 9,419 | $70.78 |
| Aug 19, 2026 | Michael Schmertzler | Sale | 5,335 | $72.86 |
PTCT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $1.73B | $682.64M | 7.78 | $711.20M |
| Dec 31, 2024 | $806.78M | $-363.30M | -4.73 | $-107.69M |
| Dec 31, 2023 | $937.82M | $-626.60M | -8.37 | $-158.42M |
| Dec 31, 2022 | $698.80M | $-559.02M | -7.79 | $-356.65M |
| Dec 31, 2021 | $538.59M | $-523.90M | -7.43 | $-251.33M |
Latest balance sheet: total assets $3.25B, total liabilities $3.42B, cash $1.05B (as of Jun 30, 2026).
PTCT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Jul 30, 2026 | 8-K Item 2.02 (results) | $75.52 |
| May 7, 2026 | 8-K Item 2.02 (results) | $64.49 |
| Feb 19, 2026 | 8-K Item 2.02 (results) | $69.90 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $77.59 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $67.72 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $50.36 |
| May 6, 2025 | 8-K Item 2.02 (results) | $36.19 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $50.57 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $44.05 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $42.96 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| Apr 25, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on PTCT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.